Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H18N6O3 |
| Molecular Weight | 294.3097 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C1=NC=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](N)[C@H]3O
InChI
InChIKey=RYSMHWILUNYBFW-GRIPGOBMSA-N
InChI=1S/C12H18N6O3/c1-17(2)10-8-11(15-4-14-10)18(5-16-8)12-9(20)7(13)6(3-19)21-12/h4-7,9,12,19-20H,3,13H2,1-2H3/t6-,7-,9-,12-/m1/s1
| Molecular Formula | C12H18N6O3 |
| Molecular Weight | 294.3097 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28420111 | https://www.ncbi.nlm.nih.gov/pubmed/28528353
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28420111 | https://www.ncbi.nlm.nih.gov/pubmed/28528353
Puromycin aminonucleoside is a semi-synthetic derivative of puromycin lacking the methoxyphenylalanyl moiety. Puromycin aminonucleoside is the key intermediate in the synthesis of semi-synthetic analogues of puromycin. It does not inhibit protein synthesis or induce apoptosis but exhibits antitumor properties. Puromycin aminonucleoside-induced nephrosis is a well-described model of human idiopathic nephrotic syndrome, suppressing expression of integrin expression in cultured glomerular epithelial cells. Puromycin aminonucleoside is used to study human glomerular disease by inducing damage of murine glomerular podocytes and is used to study glomerular function and morphology.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. | 2005-09 |
|
| Role of Fat1 in cell-cell contact formation of podocytes in puromycin aminonucleoside nephrosis and neonatal kidney. | 2005-08 |
|
| WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment. | 2005-08 |
|
| Detection and localization of proteinuria by dynamic contrast-enhanced magnetic resonance imaging using MS325. | 2005-06 |
|
| Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. | 2005-06 |
|
| Primary human glomerular endothelial cells produce proteoglycans, and puromycin affects their posttranslational modification. | 2005-04 |
|
| Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. | 2005-03-07 |
|
| Impact of cyclosporin on podocyte ZO-1 expression in puromycin aminonucleoside nephrosis rats. | 2005-02-28 |
|
| Nephrin and podocin expression around the onset of puromycin aminonucleoside nephrosis. | 2005-02 |
|
| Role of uroguanylin, a Peptide with natriuretic activity, in rats with experimental nephrotic syndrome. | 2005-02 |
|
| Hypoxia in renal disease with proteinuria and/or glomerular hypertension. | 2004-12 |
|
| Ultrastructural study on nephrin expression in experimental puromycin aminonucleoside nephrosis. | 2004-12 |
|
| Induction of antioxidant enzymes in murine podocytes precedes injury by puromycin aminonucleoside. | 2004-11 |
|
| Cell-type-specific activation of mitogen-activated protein kinases in PAN-induced progressive renal disease in rats. | 2004-10-08 |
|
| Key molecular events in puromycin aminonucleoside nephrosis rats. | 2004-09 |
|
| Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. | 2004-08-13 |
|
| Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat. | 2004-07 |
|
| Role of mast cells in the development of renal fibrosis: use of mast cell-deficient rats. | 2004-06 |
|
| Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats. | 2004-05 |
|
| Melatonin decreases apoptosis and expression of apoptosis-associated proteins in acute puromycin aminonucleoside nephrosis. | 2004-05 |
|
| Novel expression of sodium/myo-inositol co-transporter in podocytes in puromycin aminonucleoside nephrosis. | 2004-04 |
|
| Oxidative stress in a rat model of nephrosis can be quantified by electron spin resonance. | 2004-03 |
|
| Antifibrotic effect of the Chinese herbs, Astragalus mongholicus and Angelica sinensis, in a rat model of chronic puromycin aminonucleoside nephrosis. | 2004-02-13 |
|
| Increased oxidative stress and apoptosis in acute puromycin aminonucleoside nephrosis. | 2004-02 |
|
| Altered expression of NDST-1 messenger RNA in puromycin aminonucleoside nephrosis. | 2004-02 |
|
| Renal processing of serum proteins in an albumin-deficient environment: an in vivo study of glomerulonephritis in the Nagase analbuminaemic rat. | 2004-02 |
|
| Extracellular matrix regulates glomerular epithelial cell survival and proliferation. | 2004-02 |
|
| Soy protein diet ameliorates renal nitrotyrosine formation and chronic nephropathy induced by puromycin aminonucleoside. | 2004-01-09 |
|
| Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. | 2004-01 |
|
| A study of VEGF and its receptors in two rat models of proteinuria. | 2004 |
|
| Effect of grape seed extract on puromycin-aminonucleoside-induced nephrosis in rats. | 2003-09 |
|
| Retinoids as a potential treatment for experimental puromycin-induced nephrosis. | 2003-06 |
|
| MAP-LC3, a promising autophagosomal marker, is processed during the differentiation and recovery of podocytes from PAN nephrosis. | 2003-06 |
|
| Regulation of endothelin-converting enzyme 1 in nephrotic syndrome in rats. | 2003 |
|
| Increased expression of CD54, CD18, MHC class II molecules, and proliferating cell nuclear antigen in acute puromycin aminonucleoside nephrosis. | 2003 |
|
| Role of cytochrome P450 2B1 in puromycin aminonucleoside-induced cytotoxicity to glomerular epithelial cells. | 2003 |
|
| The regulation of the extracellular matrix turnover in the experimental glomerulopathies. | 1997-05-01 |
|
| Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. | 1992-12 |
|
| The altered glomerular filtration slits seen in puromycin aminonucleoside nephrosis and protamine sulfate-treated rats contain the tight junction protein ZO-1. | 1992-10 |
|
| Mechanisms involved in the progression to glomerular sclerosis induced by systemic hypertension during mild puromycin aminonucleoside nephrosis. | 1992-09 |
|
| Urinary albumin determination by gel-filtration high-performance liquid chromatography. | 1992-08 |
|
| Possible mechanism of impaired calcium and vitamin D metabolism in nephrotic rats. | 1992-08 |
|
| [The effect of elastase on aminonucleoside nephrosis--on renal vascular system]. | 1992-07 |
|
| Captopril magnifies the increase in angiotensin I-converting enzyme activity in rats with aminonucleoside nephrosis. | 1992-06 |
|
| [Effects of FK506 on aminonucleoside-induced nephrotic rats]. | 1992-02 |
|
| Tubular resistance to furosemide contributes to the attenuated diuretic response in nephrotic rats. | 1992-01 |
|
| Roles of active oxygen species in glomerular epithelial cell injury in vitro caused by puromycin aminonucleoside. | 1992 |
|
| Activity of serum enzymes in puromycin aminonucleoside-induced nephrotic syndrome. | 1992 |
|
| Glomerular epithelial cell endocytosis in puromycin-induced glomerulopathy. | 1992 |
|
| Increased glomerular atrial natriuretic peptide receptor affinity in experimental nephrotic syndrome. | 1992 |
Patents
Sample Use Guides
Rats were intravenously injected with puromycin aminonucleoside (75 mg/kg/day, dissolved in saline).
Route of Administration:
Intravenous
Conditionally immortalized human podocytes AB8/13 were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) (Life Technologies). The human podocytes proliferated at 33 C, with the addition of Insulin–Transferrin–Selenium (Life Technologies). After growing to 50–60% confluency, cells were transferred to 37 C for stopping proliferation and achieving full differentiation in 10–14 days. Fully differentiated human podocytes were treated with different reagents, such as PAN (Puromycin aminonucleoside), in RPMI 1640 medium plus 10% FBS at 37 C in a humidified atmosphere containing 5% CO2.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:55:10 GMT 2025
by
admin
on
Mon Mar 31 22:55:10 GMT 2025
|
| Record UNII |
0Q580U88V8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
58-60-6
Created by
admin on Mon Mar 31 22:55:10 GMT 2025 , Edited by admin on Mon Mar 31 22:55:10 GMT 2025
|
PRIMARY | |||
|
3056
Created by
admin on Mon Mar 31 22:55:10 GMT 2025 , Edited by admin on Mon Mar 31 22:55:10 GMT 2025
|
PRIMARY | |||
|
DTXSID7037264
Created by
admin on Mon Mar 31 22:55:10 GMT 2025 , Edited by admin on Mon Mar 31 22:55:10 GMT 2025
|
PRIMARY | |||
|
6020
Created by
admin on Mon Mar 31 22:55:10 GMT 2025 , Edited by admin on Mon Mar 31 22:55:10 GMT 2025
|
PRIMARY | |||
|
200-388-3
Created by
admin on Mon Mar 31 22:55:10 GMT 2025 , Edited by admin on Mon Mar 31 22:55:10 GMT 2025
|
PRIMARY | |||
|
42839
Created by
admin on Mon Mar 31 22:55:10 GMT 2025 , Edited by admin on Mon Mar 31 22:55:10 GMT 2025
|
PRIMARY | |||
|
0Q580U88V8
Created by
admin on Mon Mar 31 22:55:10 GMT 2025 , Edited by admin on Mon Mar 31 22:55:10 GMT 2025
|
PRIMARY |